ArticleGenes & diseases2027
Steatotic liver-derived extracellular vesicles deliver ACSL4 to potentiate hepatic ischemia-reperfusion injury by orchestrating a ferroptosis-mitochondrial apoptosis cascade.
Article in Genes & diseases, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Steatotic liver grafts exhibit heightened susceptibility to hepatic ischemia-reperfusion injury (HIRI), contributing to poor outcomes in liver transplantation; however, the underling mechanisms remain incompletely defined. Here, we demonstrate that extracellular vesicles derived from steatotic livers (HFD-EVs) exacerbate HIRI by delivering acyl-CoA synthetase long-chain family member 4 (ACSL4) to hepatocytes, thereby triggering a ferroptosis-mitochondrial apoptosis cascade. Proteomic profiling revealed that HFD-EVs are enriched with ACSL4 and other pro-ferroptotic mediators, but deficient in mitochondrial oxidative phosphorylation components. In a murine model, administration of HFD-EVs to lean mice prior to ischemia-reperfusion significantly aggravated liver injury, apoptosis, and inflammatory responses compared to EVs from healthy livers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.